Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
, , , , , , oraz
01 lut 2013
O artykule
Data publikacji: 01 lut 2013
Zakres stron: 57 - 62
DOI: https://doi.org/10.2478/raon-2013-0012
Słowa kluczowe
This content is open access.
Tuzi, Alessandro
Lombardi, Davide
Crivellari, Diana
Militello, Loredana
Perin, Tiziana
La Grassa, Manuela
Massarut, Samuele
Veronesi, Andrea